Literature DB >> 12843141

Completely skewed X-inactivation in a mentally retarded young female with pseudohypoparathyroidism type IB and juvenile renin-dependent hypertension.

Masashi Demura1, Yoshiyu Takeda, Takashi Yoneda, Kenji Furukawa, Aiko Tachi, Hiroshi Mabuchi.   

Abstract

Genetic analysis of the GNAS gene was performed in a patient with idiopathic renin-dependent hypertension, PTH resistance, and Albright's hereditary osteodystrophy-like characteristics such as a round face, short stature, obesity, and mental retardation (IQ, 49). Mutational analysis showed no mutations in exons 1-13 or in any exon-intron boundary. However, methylation-status analysis revealed a bialleic methylation defect in GNAS exon 1A, indicating that a GNAS-imprinting defect is the cause of her PTH resistance, as commonly observed in pseudohypoparathyroidism type IB. The imprinting defect, however, could not explain her renin-dependent hypertension and Albright's hereditary osteodystrophy-like phenotype. There are many types of X-linked mental retardation. Syndromic X-linked mental retardation, such as X-linked alpha-thalassemia mental retardation syndrome and Rett syndrome, is reportedly associated with abnormal imprinting. To further investigate this unexplained phenotype, we tested whether this patient showed skewed X-inactivation (SXI) presumably as a result of postinactivation selection against cells with a mutated gene on the active X-chromosome. Completely SXI was observed in the DNA from her leukocytes, urinary sediment, and renal tissue. A mutation of the X-chromosome might be correlated with this phenotype because of a close association between completely SXI and X-chromosomal mutation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843141     DOI: 10.1210/jc.2002-021527

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Madelung-like deformity in pseudohypoparathyroidism type 1b.

Authors:  Janine Sanchez; Erasmo Perera; Suzanne Jan de Beur; Changlin Ding; Anna Dang; Gary D Berkovitz; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2011-07-13       Impact factor: 5.958

2.  Sex chromosome effects unmasked in angiotensin II-induced hypertension.

Authors:  Hong Ji; Wei Zheng; Xie Wu; Jun Liu; Carolyn M Ecelbarger; Rebecca Watkins; Arthur P Arnold; Kathryn Sandberg
Journal:  Hypertension       Date:  2010-03-15       Impact factor: 10.190

Review 3.  Current Nomenclature of Pseudohypoparathyroidism: Inactivating Parathyroid Hormone/Parathyroid Hormone-Related Protein Signaling Disorder.

Authors:  Serap Turan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27

4.  Epigenetic Regulation of Aldosterone Synthase Gene by Sodium and Angiotensin II.

Authors:  Yoshimichi Takeda; Masashi Demura; Fen Wang; Shigehiro Karashima; Takashi Yoneda; Mitsuhiro Kometani; Atsushi Hashimoto; Daisuke Aono; Shin-Ichi Horike; Makiko Meguro-Horike; Masakazu Yamagishi; Yoshiyu Takeda
Journal:  J Am Heart Assoc       Date:  2018-05-08       Impact factor: 5.501

Review 5.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.